Phillips Andrew John Buys Shares of MoonLake Immunotherapeutics
Phillips Andrew John acquired 22,195 shares of MoonLake Immunotherapeutics on June 17, 2026.
Key Points
- Phillips Andrew John bought 22,195 shares of MoonLake Immunotherapeutics on June 17, 2026.
- MoonLake Immunotherapeutics, trading on NasdaqCM as MLTX, has a market cap of about $1.41 billion.
- The company develops therapies for inflammatory diseases and has a 'buy' rating from analysts.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Phillips Andrew John recently bought 22,195 shares of MoonLake Immunotherapeutics, trading on the NasdaqCM under the ticker MLTX. This transaction took place on June 17, 2026, with shares trading at approximately $19.19 each.
MoonLake Immunotherapeutics Stock Up 49.3%
Shares of NasdaqCM:MLTX traded near $19.19. MoonLake Immunotherapeutics has a market cap of about $1.41 billion and a forward P/E ratio indicating it isn't profitable yet. The stock's beta is 1.036, suggesting it has slightly more volatility than the market. Over the past 52 weeks, the stock has ranged from $5.95 to $62.75, with a 50-day moving average of $17.88 and a 200-day moving average of $19.01. The company boasts a strong current ratio of 8.601 and a quick ratio of 7.887, but it carries a debt-to-equity ratio of 39.682.
$MLTX stock price
Daily closing prices, year to date. Not investment advice.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company based in Zug, Switzerland. It focuses on developing therapies for inflammatory skin and joint diseases. The company's leading product is Sonelokimab, a novel treatment targeting IL-17A and IL-17F for conditions like hidradenitis suppurativa and psoriasis. Founded in 2021, it operates under the leadership of CEO Dr. Jorge Santos da Silva and employs around 130 people.
Bottom Line
This insider purchase by Phillips Andrew John adds an interesting dimension to MoonLake Immunotherapeutics' stock activity. The company, while not yet profitable, is making strides in the biotechnology field with its innovative treatments. Investors often watch insider transactions closely as they can hint at management's confidence in the company's future. However, it's crucial to remember that this insider activity is just one piece of the puzzle when assessing a stock's potential.
Get MoonLake Immunotherapeutics alerts
New 13F filings, insider trades, and analyst moves on $MLTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.